Ukr.Biochem.J. 2015; Volume 87, Issue 2, Mar-Apr, pp. 103-112

doi: https://doi.org/10.15407/ubj87.02.103

Metalloproteins during development of Walker-256 carcinosarcoma resistant phenotype

29.05.2015   Uncategorized   No comments

V. F. Chekhun, Yu. V. Lozovska, A. P. Burlaka, I. I. Ganusevich,
Yu. V. Shvets, N. Yu. Lukianova, I. M. Todor, D. V. Demash,
A. A. Pavlova, L. A. Naleskina

R. E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology,
National Academy of Sciences of Ukraine, Kyiv;
e-mial: Lozovskaya.2012@mail.ru

The study was focused on the detection of changes in serum and tumor metal-containing proteins in animals during development of doxorubicin-resistant phenotype in malignant cells after 12 courses of chemotherapy. We found that on every stage of resistance development there was a significant increase in content of ferritin and transferrin proteins (which take part in iron traffick and storage) in Walker-256 carcinosarcoma tissue. We observed decreased serum ferritin levels at the beginning stage of the resistance development and significant elevation of this protein levels in the cases with fully developed resistance phenotype. Transferrin content showed changes opposite to that of ferritin. During the development of resistance phenotype the tumor tissue also exhibited increased ‘free iron’ concentration that putatively correlate with elevation of ROS generation and levels of MMP-2 and MMP-9 active forms. The tumor non-protein  thiol content increases gradually as well. The serum of animals with early stages of resistance phenotype development showed high ceruloplasmin activity and its significant reduction after loss of tumor sensitivity to doxorubicin. Therefore, the development of resistance phenotype in Walker-256 carcinosarcoma is accompanied by both the deregulation of metal-containing proteins in serum and tumor tissue and by the changes in activity of antioxidant defense system. Thus, the results of this study allow us to determine the spectrum of metal-containing proteins that are involved in the development of resistant tumor phenotype and that may be targeted for methods for doxorubicin sensitivity correction therapy.

Keywords: , , , , , , , ,

References:

  1. Chekhun VF, Shpilevaia SI. Role of endogenous iron in tumor sensitization to antitumor therapy. Vopr Onkol. 2010;56(3):251-61. Review. Russian. PubMed
  2. Elliot RL, Head JF. Cancer: Tumor iron metabolism, mitochondrial dysfunction and tumor immunosuppression; ”a tight partnership-was Warburg correct?” J. Cancer Therapy. 2012;3(4):278-311. CrossRef
  3. Torti SV, Torti FM. Iron and cancer: more ore to be mined. Nat Rev Cancer. 2013 May;13(5):342-55. Review. PubMed, PubMedCentral, CrossRef
  4. Mishra S, Sharma DC, Sharma P. Studies of biochemical parameters in breast cancer with and without metastasis. Indian J Clin Biochem. 2004 Jan;19(1):71-5. PubMed, PubMedCentral, CrossRef
  5. Sosa V, Moliné T, Somoza R, Paciucci R, Kondoh H, LLeonart ME. Oxidative stress and cancer: an overview. Ageing Res Rev. 2013 Jan;12(1):376-90. Review. PubMed, CrossRef
  6. Linder MC. Mobilization of stored iron in mammals: a review. Nutrients. 2013 Oct 10;5(10):4022-50. Review. PubMed, PubMedCentral, CrossRef
  7. Beguin Y, Aapro M, Ludwig H, Mizzen L, Osterborg A. Epidemiological and nonclinical studies investigating effects of iron in carcinogenesis–a critical review. Crit Rev Oncol Hematol. 2014 Jan;89(1):1-15. Review. PubMed, CrossRef
  8. Vashchenko G, MacGillivray RT. Multi-copper oxidases and human iron metabolism. Nutrients. 2013 Jun 27;5(7):2289-313. Review. PubMed, PubMedCentral, CrossRef
  9. Buico A, Cassino C, Ravera M, Betta PG, Osella D. Oxidative stress and total antioxidant capacity in human plasma. Redox Rep. 2009;14(3):125-31. PubMed, CrossRef
  10. Zordoky BN, Anwar-Mohamed A, Aboutabl ME, El-Kadi AO. Acute doxorubicin toxicity differentially alters cytochrome P450 expression and arachidonic acid metabolism in rat kidney and liver. Drug Metab Dispos. 2011 Aug;39(8):1440-50. PubMed, CrossRef
  11. Xiangcong Xu. The molecular mechanisms of iron ferritin metabolism in normal and neoplastic cells. A thesis submitted in fulfillment of the requirements for the Degree of Doctor of Philosophy. Sydney: Lord of the rings, 2012; 214 p.
  12. Manna A, Saha P, Sarkar A, Mukhopadhyay D, Bauri AK, Kumar D, Das P, Chattopadhyay S, Chatterjee M. Malabaricone-A induces a redox imbalance that mediates apoptosis in U937 cell line. PLoS One. 2012;7(5):e36938. PubMed, PubMedCentral, CrossRef
  13. Solov’eva NI, Ryzhakova OS. Methods for determining matrix metalloproteinase activity. Klin Lab Diagn. 2010 Feb;(2):17-21. Russian. PubMed
  14. Cermak J, Balla J, Jacob HS, Balla G, Enright H, Nath K, Vercellotti GM. Tumor cell heme uptake induces ferritin synthesis resulting in altered oxidant sensitivity: possible role in chemotherapy efficacy. Cancer Res. 1993 Nov 1;53(21):5308-13. PubMed
  15. Cocco E, Porrini V, Derosas M, Nardi V, Biasiotto G, Maccarinelli F, Zanella I. Protective effect of mitochondrial ferritin on cytosolic iron dysregulation induced by doxorubicin in HeLa cells. Mol Biol Rep. 2013 Dec;40(12):6757-64. PubMed, CrossRef
  16. Kakhlon OR, Gruenbaum Y, Cabantchik ZI. Ferritin expression modulated cell cycle dynamics and cell responsiveness to H-ras-induced growth via expansion of the labile iron pool. Biochem J. 2002 May 1;363(Pt 3):431-6. PubMed, PubMedCentral, CrossRef
  17. Stern H. S. Joint Meeting of the Israel Society of Colon and Rectal Surgery (ISCRS) International Colorectal Cancer Club (ICRCC). Tech Coloproctol. 2011;15(1):115-124. CrossRef
  18. Yurchenko OV, Todor IN, Tryndyak VP. Resistance of Guerin’s carcinoma cells to cisplatine: biochemical and morphological aspects. Exp Oncol. 2003;25:64-68.
  19. Kushlinsky NE, Gershtein ES. Investigation of matrix metalloproteinases and their tissue inhibitors in the tumors and peripheral blood of cancer patients. Clinical Prospects. Laboratornia Sluzhba. 2013;1:25-38. (In Russian).
  20. Chekhun V., Lukianova N., Demash D., Borikun T., Chekhun S., Shvets Y. Manifestation of key molecular genetics markers in pharmacocorrection of endogenous iron metabolism in MCF-7 and MCF-7/DDP human breast cancer. Cell Bio. 2013;2(4):217-227. CrossRef
Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.